Kairos Pharma, Ltd. (KAPA) Financial Analysis & Valuation | Quarter Chart
Kairos Pharma, Ltd. (KAPA)
KAPAPrice: $0.6
Fair Value: 🔒
🔒score
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly know... more
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutic... more
Description
Shares
| Market Cap | $12.45M | Exchange | AMEX |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | John S. Yu |
| IPO Date | 2024-09-16 | CAGR | — |
| Employees | 1 | Website | kairospharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KAPA chart loading...
Fundamentals
Technicals
| Enterprise Value | $13.31M | P/E Ratio | -1.94 |
| Forward P/E | -1.04 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-0.31 | EPS Growth 1Y | 18.38% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.79% | ROA | -0.63% |
| ROCE | -0.73% | Current Ratio | 16.56 |
| Quick Ratio | 16.56 | Cash Ratio | 13.87 |
| Debt/Equity | — | Interest Coverage | -42.13 |
| Altman Z Score | 15.24 | Piotroski Score | 2 |